GlaxoSmithKline (GSK) - Company Value to Net Income

GSK plc is scaling its business through multi-billion dollar investments in high-margin innovative vaccines. The P/E market valuation illustrates the price action's reaction to this potential, with the 17.80 metric serving as the target level. Stable demand for HIV medications protects capital from crises, while a bet on elite biochemists and a rigorous R&D approach strengthens the fundamental value of the behemoth.

GSK GSK plc: Price to Earnings Ratio in the range 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for GlaxoSmithKline plc (GSK)

- share price and expert price forecast:

Price Performance Chart GSK Corp|GSK - Analyst Consensus Forecast

- market capitalization indicators:

Market Value GlaxoSmithKline|GSK - Total Company Value

- balance sheet net asset value indicators:

Net Asset Value per Share GSK|GSK - Company Book Value|Market Value to Book Value Ratio gsk.com|GSK - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

GSK - Company Net Income|Company Profit Forecast GSK plc|GSK - Price to Earnings Ratio|Forward P/E Multiple GSK Corp|GSK - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation GlaxoSmithKline|GSK - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months GSK|GSK - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months gsk.com|GSK - Earnings growth in current year|Expected earnings per share growth for next year GSK plc

Comprehensive company analysis:gsk.com GSK

The maturity of the vaccine portfolio and the R&D pipeline updates at GSK plc (GSK) determine the current market value of the business. The ratio of market capitalization to net income, reflected in the company's trailing twelve months (TTM) P/E ratio, measures the premium for asset scalability. This chart's price action allows for the identification of undervaluation points or risks of technological obsolescence. The final indicator value demonstrates the level of investor confidence in the issuer's capital management efficiency.

Key competitors